Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

Pharvaris N.V.
Pharvaris N.V.
Pharvaris N.V.
3 min read

In This Article:

ZUG, Switzerland, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of six abstracts, two for oral presentation and four for poster presentation, at the 2024 Global Angioedema Forum – HAEi Global Leadership Workshop, taking place in Copenhagen, Denmark, from Oct. 4-5, 2024. Details are as follows:

  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
    Presenter: Marc A. Reidel, M.D., M.S.
    Format: Oral and Poster
    Date, time: Oral: Saturday, Oct. 5, Session 5, 9:59 CEST (3:59 a.m. EDT) | Poster: Friday, Oct. 4, 18:00-18:30 CEST (12:00-12:30 p.m. EDT), Poster Walk 1

  • Title: Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
    Presenter: Anna Valerieva, M.D., Ph.D.
    Format: Oral and Poster
    Date, time: Oral: Saturday, Oct. 5, Session 5, 10:08 CEST (4:08 a.m. EDT) | Friday, Oct. 4, 18:30-19:00 CEST (12:30-1:00 p.m. EDT), Poster Walk 4

  • Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
    Presenter: Emel Ayg?ren-Pursun, M.D.
    Format: Poster
    Date, time: Friday, Oct. 4, 18:00-18:30 CEST (12:00-12:30 p.m. EDT), Poster Walk 3

  • Title: Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
    Presenter: Andrea Zanichelli, M.D., Ph.D.
    Format: Poster
    Date, time: Friday, Oct. 4, 18:30-19:00 CEST (12:30-1:00 p.m. EDT), Poster Walk 2

  • Title: Propensity Score-Matched Comparison of Outcomes for Deucrictibant vs. Standard of Care in People Living with Hereditary Angioedema
    Presenter: Danny M. Cohn, M.D., Ph.D.
    Format: Poster
    Date, time: Friday, Oct. 4, 18:30-19:00 CEST (12:30-1:00 p.m. EDT), Poster Walk 2

  • Title: Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
    Presenter: Phillip H. Li, MBBS, FRCP
    Format: Poster
    Date, time: Friday, Oct. 4, 18:00-19:00 CEST (12:00-1:00 p.m. EDT), Poster Walk 1

The presentation slides and posters will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.

Recommended Stories